 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
|
|
|
|
Phase II, Phase I
|
|
|
|
8717
NCT00673114
|
|
| |
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
|
|
|
Phase II, Phase I
|
|
|
|
CRUK-BRD/07/004
CRUK-BRD/07/004, 2007-002570-58, EU-20861, NCT00727831
|
|
| |
A Study of Tor Kinase Inhibitor in Advanced Tumors
|
|
|
|
Phase II, Phase I
|
|
|
|
D1600C00001
2008-002606-19, NCT00731263
|
|
| |
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
|
|
|
|
Phase II, Phase I
|
|
|
|
CL-CPI-613-002
NCT00741403
|
|
| |
High Dose, Absorbed Dose Adjusted 90Y-Ibritumomab With PBSC Support in B-Cell Lymphoma
|
|
|
|
Phase II, Phase I
|
|
|
|
6th radioimmunotherapy prot.
EudraCT number: 2007-002762-35, NCT00761384
|
|
| |
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
|
|
|
Phase II
|
|
|
|
CALGB-50202
CALGB-50202, NCT00098774
|
|
| |
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
|
|
|
|
Phase II
|
|
|
|
BCM-H-16155
NCT00109798
|
|
| |
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
|
|
|
|
Phase II
|
|
|
|
NABTC-05-01
NABTC-05-01, NCT00248534
|
|
| |
Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host
|
|
|
|
Phase II
|
|
|
|
240801-HMO-CTIL
NCT00149032
|
|
| |
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
|
|
|
|
Phase II
|
|
|
|
IELSG20
NCT00210314
|
|
